Patents by Inventor Wayne C. Schairer
Wayne C. Schairer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11834444Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: July 6, 2017Date of Patent: December 5, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston, Timothy Claude Barden, Wayne C. Schairer
-
Publication number: 20230339928Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: ApplicationFiled: April 28, 2023Publication date: October 26, 2023Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Patent number: 11708361Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: October 8, 2021Date of Patent: July 25, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Patent number: 11274096Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: GrantFiled: January 10, 2019Date of Patent: March 15, 2022Assignee: Cyclerion Therapeutics, Inc.Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Publication number: 20220024909Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: ApplicationFiled: October 8, 2021Publication date: January 27, 2022Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Publication number: 20210284632Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: ApplicationFiled: July 6, 2017Publication date: September 16, 2021Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston, Timothy Claude Barden, Wayne C. Schairer
-
Publication number: 20210053962Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as simulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said simulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.Type: ApplicationFiled: January 10, 2019Publication date: February 25, 2021Inventors: Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
-
Publication number: 20140187795Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as CRTH2 antagonists. Compounds prepared by the processes of the invention are of Formula (AI), (All) and Compound (I).Type: ApplicationFiled: June 17, 2011Publication date: July 3, 2014Applicant: Ironwood Pharmaceuticals, Inc.Inventors: James Jia, Regina Graul, Wayne C Schairer, Vishnu Karnati, Ray Forslund
-
Publication number: 20130178453Abstract: The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I).Type: ApplicationFiled: February 9, 2011Publication date: July 11, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Jason Rohde, Bo Peng, Takashi Nakai, Kevin Sprott, Ara MermerÃan, Wayne C. Schairer, Galen John Carey
-
Patent number: 8426359Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: GrantFiled: November 5, 2008Date of Patent: April 23, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
-
Publication number: 20090292135Abstract: The invention relates to chemical genera of organometal benzenephosphonates useful in cross-coupling organic synthesis, having general formula: where R is selected from boron, zinc, tin and silicon residues.Type: ApplicationFiled: May 9, 2006Publication date: November 26, 2009Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley, JingJing Yang
-
Publication number: 20090291902Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: ApplicationFiled: November 5, 2008Publication date: November 26, 2009Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik, Wayne C. Schairer
-
Publication number: 20090131395Abstract: The invention relates to a chemical genus of 4-biphenyl-1-phenylazetidin-2-ones useful in the treatment of hypercholesterolemia and other disorders. The compounds have the general formula I: Pharmaceutical compositions and methods for treating cholesterol- and lipid-associated diseases are also disclosed.Type: ApplicationFiled: May 5, 2006Publication date: May 21, 2009Applicant: MICROBIA, INC.Inventors: Stephen Antonelli, Regina Lundrigan, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley, Timothy C. Barden, JingJing Yang, Daniel P. Zimmer
-
Publication number: 20090099355Abstract: The present invention relates to processes for the production of 4-(biphenylyl)azetidin-2-one phosphonic acid derivatives of formulaType: ApplicationFiled: May 25, 2006Publication date: April 16, 2009Applicant: MICROBIA, INC.Inventors: Stephen Antonelli, Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
-
Publication number: 20080287663Abstract: The present invention relates to processes for the production of 4-biphenylylazetidin-2-one derivatives of formulaType: ApplicationFiled: May 8, 2006Publication date: November 20, 2008Applicant: MICROBIA, INC.Inventors: Peter Lee, Stephen Antonelli, Regina Lundrigan, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
-
Publication number: 20080200669Abstract: The present invention relates to processes for the production of phenolic 4-biphenylylazetidin-2-one derivatives of formulaType: ApplicationFiled: May 11, 2006Publication date: August 21, 2008Applicant: Microbia, Inc.Inventors: Timothy C. Barden, Peter Lee, Eduardo J. Martinez, Wayne C. Schairer, John J. Talley
-
Publication number: 20080167255Abstract: 4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.Type: ApplicationFiled: December 11, 2007Publication date: July 10, 2008Applicant: MICROBIA, INC.Inventors: Eduardo J. Martinez, John J. Talley, Stephen Antonelli, Timothy C. Barden, Regina Lundrigan-Soucy, Wayne C. Schairer, Jing-Jing Yang, Daniel P. Zimmer, Brian Cali, Mark G. Currie, Peter S. Yorgey
-
Patent number: 7320972Abstract: 4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.Type: GrantFiled: November 10, 2004Date of Patent: January 22, 2008Assignee: Microbia, Inc.Inventors: Eduardo Martinez, John J. Talley, Stephen Antonelli, Timothy C. Barden, Regina Lundrigan-Soucy, Wayne C. Schairer, Jing-Jing Yang, Daniel P. Zimmer, Brian Cali, Mark G. Currie, Peter S. Yorgey